Last reviewed · How we verify
Ginkgo biloba pills
At a glance
| Generic name | Ginkgo biloba pills |
|---|---|
| Sponsor | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI (PHASE2)
- Gastrodin Acupoint Injection for Sensorineural Hearing Loss With Vertigo (NA)
- The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature
- Aleeto in Acute ISchemic Stroke：A RandomISed Controlled Clinical Trial (PHASE2)
- The Study of Ginkgo Leaf Dropping Pills and Huperzine a Injection Combined with Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury (PHASE4)
- Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD (PHASE4)
- Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke (NA)
- Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ginkgo biloba pills CI brief — competitive landscape report
- Ginkgo biloba pills updates RSS · CI watch RSS
- Xiyuan Hospital of China Academy of Chinese Medical Sciences portfolio CI